Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 39Recruiting 28Terminated 25Unknown 19Active not recruiting 11Not yet recruiting 3Enrolling by invitation 2Withdrawn 1Suspended 1No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 46Breast Neoplasms 46Colorectal Neoplasms 27Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Glioblastoma 19Melanoma 17Lung Neoplasms 17Pancreatic Neoplasms 16Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Ovarian Neoplasms 13Brain Neoplasms 13Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Sarcoma 7Rectal Neoplasms 7Leukemia 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Neoplasms by Histologic Type × Clear all
NCT03722186 2021-03-22

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Suspended
128 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Neoplasms by Histologic Type, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡